Half of Americans ages 45-80 have Atherosclerosis, a buildup of plague within the arteries. There are medications for the disease, however, they have been known to cause excessive bleeding, toxicity, and have short circulation time. There maintains a need to develop a nontoxic, biocompatible solution to Atherosclerosis with significant circulation time. Researchers discuss in, "Liposome interaction with macrophages and foam cells for atherosclerosis treatment: effects of size, surface charge and lipid composition" a potential liposomal formulation to solve these problems. They tested formulations using DPPC, DSPC, EPC and ESM lipids. Each of the lipid formulations were able to decrease cholesterol, however DPPC and DSPC were most effective. Anionic liposomes were shown to increase Cholesterol efflux more than cationic or neutral liposomes. The highest Cholesterol efflux was observed at 500 µM of lipid. These are all great points to consider when developing a new therapy for Atherosclerosis.
top of page
Recent Posts
See AllThe article touches on: ⚪ Lipid Selection and Classification (Drug Product) ⚪ RNA Impurities and Classification (Drug Substance) ⚪...
360
I want to extend my most sincere gratitude to the Parenteral Drug Association (PDA) for allowing me to present on drug delivery systems...
390
bottom of page
Comments